To investigate striatal and cortical pre-and postsynaptic dopaminergic function in parkin-linked parkinsonism, 13 unrelated patients homozygous or compound heterozygous for parkin mutations were studied with [ 18 F]dopa and [ 11 C]raclopride (RAC) PET. Data were compared with a young-onset Parkinson's disease (YOPD) cohort, matched for age, disease severity and duration, but negative for parkin mutations. Signi®cant changes in [ 18 F]dopa uptake and RAC binding potential (BP) were localized in striatum using regions of interest (ROIs) and throughout the entire brain volume with statistical parametric mapping (SPM). As expected, both YOPD and parkin patients showed signi®cant decreases in striatal [ 18 F]dopa uptake; however, in parkin patients, additional reductions in caudate and midbrain were localized with SPM. The RAC-BP was signi®cantly decreased in striatal, thalamic and cortical areas (temporal, orbito-frontal and parietal cortex) in parkin compared with YOPD patients. Our [ 18 F]dopa PET ®ndings suggest that, compared with YOPD, parkin disease is associated with more severe and widespread presynaptic dopaminergic de®cits. The global decreases in D2 binding found in parkin compared with YOPD patients could be a direct consequence of the parkin genetic defect itself or a greater susceptibility to receptor downregulation following long-term dopaminergic agent exposure. Cortical reductions in D2 binding may contribute to the behavioural problems reported in parkin patients. 
Summary
To investigate striatal and cortical pre-and postsynaptic dopaminergic function in parkin-linked parkinsonism, 13 unrelated patients homozygous or compound heterozygous for parkin mutations were studied with [ 18 F]dopa and [ 11 C]raclopride (RAC) PET. Data were compared with a young-onset Parkinson's disease (YOPD) cohort, matched for age, disease severity and duration, but negative for parkin mutations. Signi®cant changes in [ 18 F]dopa uptake and RAC binding potential (BP) were localized in striatum using regions of interest (ROIs) and throughout the entire brain volume with statistical parametric mapping (SPM). As expected, both YOPD and parkin patients showed signi®cant decreases in striatal [ 18 F]dopa uptake; however, in parkin patients, additional reductions in caudate and
Introduction
Mutations in the gene designated parkin (PARK2, OMIM 602544) recently have been identi®ed in a number of families with autosomal-recessive juvenile parkinsonism and isolated young-onset cases Leroy et al., 1998; Abbas et al., 1999) . The parkin phenotype, although in many respects similar to that of idiopathic Parkinson's disease (IPD), is often characterized by early-onset parkinsonism, foot dystonia, diurnal¯uctuations, slow progression, a good response to anticholinergics and exquisite dose sensitivity to L-dopa, and the frequent occurrence of behavioural and Brain Vol. 127 No. 6 ã Guarantors of Brain 2004; all rights reserved neuropsychiatric complications (Ishikawa and Tsuji, 1996; Hattori et al., 1998; Khan et al., 2002a) . Autopsied cases of parkin-linked parkinsonism have generally shown degeneration of nigral dopaminergic neurons in the absence of Lewy body inclusions (Yamamura et al., 1973; Takahashi et al., 1994; Mori et al., 1998; Maruyama et al., 2000; Van de Warrenburg et al., 2001) . The parkin gene on chromosome 6q25±27 is known to code for a ubiquitin ligase involved in protein degradation presumably leading to aberrant accumulation of cell proteins resulting in neuronal dysfunction and death (Matsumine et al., 1997; Shimura et al., 2001) .
[ 18 F]Dopa PET allows the study of regional cerebral aromatic amino acid decarboxylase (AADC) activity, a marker of the functional integrity of presynaptic dopamine nerve terminals. [ 11 C]Raclopride (RAC) PET is an in vivo marker of dopamine D2/D3 receptor binding (Garnett et al., 1983; Farde et al., 1986; Firnau et al., 1987; Martin et al., 1989; Brooks et al., 1990) . To date, combined studies of presynaptic dopaminergic function and postsynaptic D2 receptor binding have only been reported for single parkin carriers and two parkin kindreds and just at a striatal level (Broussolle et al., 2000; Hilker et al., 2001; Portman et al., 2001; Pramstaller et al., 2002; Thobois et al., 2003) . As a consequence, possible cortical dopaminergic changes in these patients have not been investigated.
The purpose of the present study was to: (i) examine patterns of disruption of pre-and postsynaptic dopaminergic function across the whole brain in a group of unrelated parkin patients using [ 18 F]dopa and RAC PET; and (ii) determine whether differences in dopaminergic status were evident between parkin patients and young-onset Parkinson's disease (YOPD) patients negative for parkin mutations.
[ 18 F]Dopa and RAC PET ®ndings were compared between young-onset parkin-positive and parkin-negative patients and an older group of IPD patients all matched for clinical disease severity.
Methods

Subjects
Thirteen patients homozygous or compound heterozygous for parkin gene mutations have been identi®ed from a cohort of unrelated sporadic Parkinson's disease patients with disease onset below age 40 years (YOPD; Table 1 ). Eleven of these 13 parkin-positive and 10 parkin-negative YOPD patients, matched for age, disease duration and severity, underwent [ 18 F]dopa PET ( Table 2 ). The PET ®ndings for the YOPD patients were also compared with those of a group of 11 older IPD patients with similar disease severity but signi®cantly shorter disease duration.
Eight out of the 13 parkin-positive YOPD patients underwent RAC PET, and ®ndings were compared with those for nine of the 10 YOPD patients negative for parkin mutations who were also scanned with [ 18 F]dopa PET. Additionally, a group of seven older IPD patients with similar disease severity but signi®cantly shorter disease duration had RAC PET. [ 18 F]Dopa and RAC PET ®ndings for parkinsonian cases were also compared with those for separate groups of 16 and 10 normal control subjects, respectively, agematched to YOPD.
All parkin-positive and parkin-negative patients ful®lled the UK Parkinson's Disease Society Brain Bank diagnostic criteria for IPD (Gibb and Lees, 1988) . In all patients, the disease severity was measured using the Hoehn and Yahr scale (Hoehn and Yahr, 1967) and the Uni®ed Parkinson's Disease Rating Scale (UPDRS) in offdrug states (Fahn and Elton, 1987) . All patients were receiving regular levodopa therapy (minimum 450 mg daily; maximum 1200 mg daily) except one patient, who was on an apomorphine pump. In addition, ®ve of the parkin-positive patients and four of the parkin-negative patients were taking adjunct dopamine agonist medication. One patient of the parkin-positive group and two patients of the parkin-negative group were taking amantadine.
Our patient subgroups comprised a higher number of males than females. Female striatal [ 18 F]dopa and RAC uptake values lay within 1 SD of corresponding mean male values. Due to ethical issues, control subjects were males, since administering radioisotopes to healthy females could affect female germ cells more severely as they are not renewed, in contrast to male germ cells. This study was approved by the Ethics Committee of the Hammersmith Hospitals Values represent the means (T 1 SD). Intergroup differences were calculated by one-way ANOVA with post hoc LSD correction (least statistical signi®cance). *P < 0.01 and **P < 0.001 versus the parkin-positive and parkin-negative group. HY = Hoehn and Yahr. Values represent the means (T 1 SD). Intergroup differences were calculated by one-way ANOVA with post hoc LSD correction (least statistical signi®cance). *P < 0.05; **P < 0.01; ***P < 0.001versus normal controls. ² P < 0.05 versus parkin-negative patients. + P <0.001; ++ P < 0.01 from overall ANOVA.
Trust, London, UK and by the Administration of Radioactive Substances Advisory Committee (ARSAC), UK. Subjects' consent was obtained according to the Declaration of Helsinki.
Molecular analysis PARK2 PCR ampli®cation and sequence analysis
The 12 coding exons of the parkin gene were ampli®ed from genomic DNA by polymerase chain reaction (PCR) using primers previously described, except for the primer for exon 3, for which exonic primers Ex3iFor and Ex3iRev were used Abbas et al., 1999) . The same primers were used for the sequencing of the PCR products of the 12 exons on both strands using the Big Dye Terminator Cycle Sequencing Ready Reaction DNA Sequencing kit (Applied Biosystems, Foster City, CA), on an ABI 3100 automated sequencer with the Sequence Analysis v.3.4.1 (Applied Biosystems) software.
PARK2 semi-quantitative PCR
Exon deletions/duplications were screened using a semi-quantitative PCR protocol as previously described . The PCR products were analysed on an ABI 377/3100 automated sequencer and Genescan v.3.1.2 and Genotype v.2.5.1 software (Applied Biosystems). Deletions and insertions of bases were deduced from the size of the PCR products.
Scanning protocol
[ 18 F]Dopa and RAC PET were performed in patients and control subjects with a CTI-Siemens ECAT EXACT HR++/966 positron emission tomograph (CTI, Knoxville, TN) which has an axial ®eld of view of 23.4 cm. Emission scan data were acquired in a highsensitivity, three-dimensional mode giving mean reconstructed fullwidth at half-maximum (FWHM) transaxial and axial spatial resolutions of 4.8 T 0.2 and 5.6 T 0.5 mm, respectively (Spinks et al., 2000) . A correction for tissue attenuation of 511 KeV gradiation was measured with a 5 min 3D transmission scan performed prior to tracer injection and acquired using a retractable 137 Cs source. Analysis of data was performed on a SUN Ultra 10 workstation (Sun Microsystems, Silicon Valley, CA).
To minimize artefacts arising from head motion, subjects were positioned within a moulded head holder such that their orbitomeatal line was parallel to the transaxial plane of the tomograph. No obvious linear/streak artefacts from movement were evident in our statistical parametric mapping (SPM) series. Head position was carefully monitored with a video camera and by direct observation throughout. Each patient had his anti-parkinsonian medication stopped at least 12 h before PET. Patients were pre-treated with 150 mg of carbidopa to block peripheral dopa-decarboxylase activity and hence prolong the availability of (Patlak et al., 1983) .
RAC PET
Following the intravenous injection of a bolus of 110±129 MBq of RAC, a dynamic time series of 26 frames over a period of 90 min 30 s (1 Q 30 s; 1 Q 15 s; 1 Q 5 s; 1 Q 10 s; 1 Q 30 s; 4 Q 1 min; and 17 Q 5 min) was acquired starting 30 s prior to injection. Parametric images of RAC-binding potential (RAC-BP) were generated at a voxel level from the dynamic RAC scan time series using a basis function implementation of the simpli®ed reference region compartmental model with the cerebellum as the reference tissue (Gunn et al., 1997) .
Data analysis
Two methods of analysis were employed: (i) a region of interest (ROI) approach; and (ii) SPM, allowing exploratory voxel by voxel group comparisons throughout the entire brain volume without requiring an a priori hypothesis.
Four ROIs were outlined by inspection of integrated transversal RAC and [ 18 F]dopa PET images using Analyze software (version 7.5, BRU, Mayo Foundation, Rochester, MN). These included the head of the caudate nucleus (circle 10 Q 10 mm), the anterior part of the putamen (circle 10 Q 10 mm), the posterior part of the putamen (circle 10 Q 10 mm) and the entire putamen (ellipsis 10 Q 24 mm).
Caudate and putaminal asymmetry indices (AIs) were calculated, re¯ecting the percentage difference between the PET signal in the respective region of higher tracer uptake compared with the contralateral region. AI = (higher PET signal ± lower PET signal/higher PET signal) Q 100 Additionally, the hemispheric ratio between the caudate and putaminal PET signal was measured. Right and left caudate and putaminal [ 18 F]dopa K i 0 and RAC-BP were averaged for each subject to allow for one-way analysis of variance (ANOVA) and post hoc LSD (least signi®cant difference). For multiple comparisons between groups, a Bonferroni correction was applied. Statistical analyses were carried out using a commercial software package (SPSS for Windows 8.0, Surrey, UK).
SPM was performed using the software package SPM99 (Wellcome Department of Cognitive Neuroscience, Institute of Neurology, Queen Square, London, UK) implemented in Matlab 5.3 (Mathworks Inc., Sherborn, MA) (Friston et al., 1995) . In order to localize signi®cant changes in [ 18 F]dopa K i 0 and RAC-BP at a voxel level, between-groups individual images were normalized into standard stereotaxic MNI (Montreal Neurological Institute) space with SPM. Spatial normalization of parametric maps was achieved by generating individual integrated`add images' (combined time frames 1±26 of the dynamic data set) and normalizing those onto inhouse made [ 18 F]dopa and RAC templates. Subsequently, the resulting transformation parameters were applied to the patient's corresponding parametric [ 18 F]dopa K i 0 and RAC-BP images. A Gaussian kernel (6 Q 6 Q 6 mm) was then convolved with the spatially normalized parametric images to smooth them in order to accommodate inter-individual anatomic variability and to improve signal to noise for the statistical analysis. Since dopamine uptake and D2 receptor density are known to be low in the occipital lobe and the cerebellum, a brain mask for those areas was created in order to minimize voxels of no interest for multicomparison corrections. A total of 61 774 voxels were analysed. The obtained data sets allowed for categorical comparisons of mean [ 18 F]dopa K i 0 values and RAC-BP among the parkin-positive, parkin-negative and control groups.
Results
ROI analysis of [ 18 F]dopa
Regional mean [ 18 F]dopa K i 0 and RAC-BP of the study groups and the intergroup statistics are detailed in Table 3 . One-way ANOVA showed a signi®cant decrease of caudate (P < 0.001) and putamen (P < 0.001) [ 18 F]dopa uptake in parkin-positive patients, parkin-negative YOPD patients, and in IPD versus normal control subjects. Parkin-positive and parkin-negative YOPD patients and IPD cases had similar levels and patterns of striatal [ 18 F]dopa uptake. Comparing parkinsonian patient groups with the normal control group, the asymmetry index of [ 18 F]dopa uptake was signi®cantly increased in the caudate (parkin-positive group, P < 0.01; parkin-negative YOPD group, P < 0.01; IPD group, P < 0.05) and putamen (parkin-positive group, P < 0.05; parkinnegative YOPD group, P < 0.001; IPD group, P < 0.05). No signi®cant difference in striatal [ 18 F]dopa asymmetry was found between parkin-positive and parkin-negative YOPD patients and IPD patients. The caudate to putamen ratio of [ 18 F]dopa K i 0 was signi®cantly increased in parkin-positive (P < 0.001), parkin-negative (P < 0.001) and IPD patients (P < 0.001) versus control subjects. There was no signi®cant difference in caudate and putamen [ 18 F]dopa uptake, the AI and the ratio between caudate and putamen comparing parkin-negative YOPD patients and the IPD group.
ROI analysis of RAC PET
One-way ANOVA revealed signi®cant reductions in caudate and putamen RAC-BP in parkin-positive patients compared with parkin-negative YOPD patients (caudate P < 0.05 and putamen P < 0.05) and control subjects (caudate and putamen P < 0.001). Parkin-negative YOPD patients showed signi®-cant decreases of caudate (P < 0.01) and anterior putamen BP (P < 0.05) when compared with healthy controls. RAC-BP was signi®cantly decreased in the caudate of the IPD group versus control subjects (P < 0.01). The asymmetry indices were not signi®cantly different among the four groups; however, we found signi®cant decreases of the caudate to putamen ratio in the three patient groups when compared with the control group (parkin-positive patients, P < 0.01; parkinnegative patients, P < 0.01, IPD group, P < 0.01). There was no signi®cant difference in caudate and putamen RAC-BP and AI and the ratio between caudate and putamen comparing parkin-negative YOPD patients and the IPD group.
[ 18 F]Dopa PET SPM ®ndings (Table 4A) SPM of parametric [ 18 F]dopa K i 0 images con®rmed the results of the putaminal ROI analysis. However, signi®cant relative decreases of K i 0 values were also localized bilaterally in the caudate of parkin-positive compared with parkin-negative YOPD patients (Fig. 1, Table 4A ). Furthermore, we found signi®cant decreases in [ 18 F]dopa K i 0 values in the ventral and dorsal midbrain in the parkin-positive patients (areas of the red nucleus, substantia nigra and raphe nuclei) compared with both parkin-negative YOPD patients and controls. No signi®cant increases in [ 18 F]dopa K i 0 values were detected in the parkin-positive group versus the parkin-negative YOPD and control groups. Comparing the parkin-negative YOPD with the IPD group, no signi®cant differences were apparent (data not shown). When compared with control subjects, signi®cant reductions of [ 18 F]dopa signal were RAC PET SPM ®ndings (Table 4B) The categorical comparison of striatal RAC-BP between parkin-positive and parkin-negative YOPD patients re¯ected the results obtained from the ROI analysis, showing signi®-cant relative reduction of RAC-BP in the caudate and putamen in the parkin-positive group. Additionally, signi®-cant relative reductions in RAC-BP were localized in the parietal cortex, temporal cortex and bilaterally in the prefrontal cortex. When compared with controls, parkinpositive patients showed widespread decreases in RAC-BP over cortical [Brodmann area (BA) 10; 21; 22; 40 (bilateral) ; 37 (right)], striatal and thalamic (medial dorsal nucleus, bilateral) areas. Signi®cant reductions of RAC-BP in parkin-negative YOPD patients versus controls were localized in the left and right caudate and anterior putamen, in the thalamus and parieto-temporal cortical areas (Table 4B) . No signi®cant differences in RAC-BP were observed in the group of parkin-negative YOPD patients when compared with IPD patients.
Discussion
This is the ®rst [ 18 F]dopa and RAC-PET study to characterize, within the entire brain volume, abnormalities in pre-and postsynaptic dopaminergic function in a group of sporadic patients with parkin-linked parkinsonism.
ROI analysis revealed a severe reduction of caudate and putaminal [ 18 F]dopa uptake in parkin-positive and parkinnegative YOPD patients and in IPD when compared with controls. A similar striatal pattern of reduced [ 18 F]dopa uptake in parkin-positive and parkin-negative YOPD patients was evident with both groups showing the typical IPD posterior±anterior gradient with most prominent loss in the posterior part of the putamen. These ®ndings are in line with previously published case reports (Broussolle et al., 2000; Hilker et al., 2001; Portman et al., 2001; Khan et al., 2002a; Thobois et al., 2003) .
SPM interrogation of [ 18 F]dopa uptake, comparing parkinpositive and parkin-negative YOPD patients, localized signi®cant symmetrical relative reductions in the caudate and midbrain areas of parkin-positive patients. A possible explanation for the failure of the ROI approach to detect these caudate decreases in the parkin-positive cases may be that the ROIs sampled the dorsal head of caudate, whereas SPM localized relative reductions in the body of the nucleus. Furthermore, ROI analysis is based on sampling brain volumes with a priori categorical assumptions as to their size and shape, whereas no a priori hypothesis regarding the localization of PET signal change is required by SPM. Monoaminergic neurons in striatal regions are predominantly dopaminergic and so [ 18 F]dopa PET provides a marker of functional integrity of nigrostriatal dopaminergic neurons. However, in midbrain areas, [ 18 F]dopa is taken up not only by dopaminergic neurons but also by serotoninergic and noradrenergic neurons expressing AADC (Tison et al., 1991) . Consequently, reduced [ 18 F]dopa K i 0 in the dorsal and ventral midbrain of the parkin-positive group may imply a more widespread dysfunction of catecholaminergic and serotoninergic neurotransmitter systems. This would be in line with the recently reported neuropathological ®ndings of loss of pigmented neurons and gliosis in both the substantia nigra pars compacta and locus coeruleus in patients with parkin mutations in the absence of Lewy bodies (Hayashi et al., 2000) . Decreases in midbrain [ 18 F]dopa uptake have also been reported in IPD patients with advanced disease (Rakshi et al., 1999) .
The discordance between moderate disability and severe nigrostriatal dopaminergic dysfunction in parkin patients parallels ®ndings reported for patients with parkinsonism due to PARK6 (Khan et al., 2002b) . It suggests that signi®cant dopamine cell loss occurs early, but then progresses slowly enough to allow compensatory mechanisms to develop. No signi®cant [ 18 F]dopa K i 0 reductions were found in cortical regions on comparing parkin-positive and parkin-negative YOPD patients with normal controls. In agreement with our ®ndings, Rakshi et al. (1999) using SPM also detected no signi®cant reductions in frontal [ 18 F]dopa K i 0 in advanced IPD, suggesting that AADC activity is maintained in this area. It has also been observed recently that, even in advanced stages of the disease, the release of endogenous dopamine in prefrontal cortical areas after amphetamine is similar to that of normal subjects .
When comparing parkin-negative patients with older IPD patients matched for disease severity, no signi®cant differences in mean regional cerebral [ 18 F]dopa K i 0 values were found. The effect of age on [ 18 F]dopa K i 0 values in healthy subjects has remained a controversial issue. Two studies found a mild inverse relationship between age and striatal [ 18 F]dopa K i 0 values (Martin et al., 1989; Laasko et al., 2002) , whereas others found no correlation Eidelberg et al., 1993; . If a decline of striatal [ 18 F]dopa K i 0 is associated with age, our data would indicate that [ 18 F]dopa uptake in YOPD patients is either similarly or more affected than in IPD patients with similar disease severity.
Both ROI analysis and SPM detected signi®cant and uniform decreases of RAC-BP in the caudate and putamen of parkin-positive patients compared with parkin-negative cases. This ®nding in sporadic parkin patients is in line with the study of Hilker et al. (2001) who reported decreases in caudate and putaminal RAC-BP in ®ve members of the same parkin kindred. Compared with controls, RAC-BP was signi®cantly reduced in the caudate but not in the putamen of parkin-negative YOPD and IPD patients. These ®ndings are in keeping with other RAC-PET and neuropathological data indicating that putamen dopamine D2 receptor binding remains normal in treated patients with IPD (Guttman et al., 1985; Ahlskog et al., 1991; Brooks et al., 1992; Grif®ths et al., 1994; Antonini et al., 1997) . Over the 31±74 year age range of normal control subjects, a mild but insigni®cant decline in RAC-BP has been reported, while a steep decline in striatal D2 receptor densities has been noted over the ®rst three decades of life (Brooks et al., 1992; Antonini et al., 1993 ). There appears to be little further loss of D2 sites in later life. In our study no statistical difference with regard to mean age was apparent when comparing patient groups versus controls, although patients were on average 8 years older than control subjects. Assuming that putaminal RAC-BP declines bỹ 0.6% per year (Antonini et al., 1993) , one would expect at most a 5% decline of RAC-BP in our patient groups compared with normal subjects, whereas there was an observed 18% reduction of putaminal RAC binding.
While nigral degeneration of dopaminergic neurons results in an initial 10±20% upregulation of D2 receptor binding in early IPD, adaptive postsynaptic mechanisms and treatment exposure normalize this as the condition advances (Brooks et al., 1992; Ahlskog et al., 1991; Antonini et al., 1997) . This viewpoint is supported by animal studies: RAC-BP was normal in four parkinsonian rhesus monkeys that had been treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 6± 7 years before PET and never received antiparkinsonian treatment (Doudet et al., 2000) . As initial putamen D2 receptor upregulation normalizes in chronically medicated patients with IPD, the reduced D2 availability found in parkin-linked parkinsonism suggests that the genetic defect itself may be responsible rather than loss of dopamine projections or exposure to medication. Longitudinal studies on striatal D2 site density in cohorts of untreated and treated parkin patients are required to clarify the issue. (Lidow et al., 1989; Kessler et al., 1993; Hall et al., 1996) . Although the D2/ D3 receptor af®nity for [ 11 C]FLB is~100 times higher than it is for RAC (Halldin et al., 1995) , recent improvement of PET scanner sensitivity and use of SPM have revealed signi®cant reductions in RAC-BP in prefrontal, temporal, parietal and thalamic areas when normal subjects receive D2 receptor antagonist neuroleptics (unpublished data) and in patients with Huntington's disease as a consequence of disease progression . Signi®cant reductions in extrastriatal RAC-BP were observed in thalamic, temporal, parietal and prefrontal brain areas of parkin patients when compared with controls and patients with parkin-negative YOPD. RAC-BP was also signi®cantly decreased in thalamic, temporal, parietal and frontal brain areas of patients with parkin-negative YOPD versus control subjects. The latter ®nding is in line with a recently published study investigating [ 11 C]FLB distribution in medicated patients with IPD (Kaasinen et al., 2000) . To date, there are no studies correlating cortical D2 receptor status and clinical symptoms. It has been reported that patients with parkin mutations have an increased prevalence of behavioural and neuropsychiatric disorders in comparison with patients with IPD (Khan et al., 2002a) . A retrospective analysis of the clinical notes revealed symptoms such as depression (two patients), panic attacks (three patients) and paranoia (one patient) in our patients with parkin-linked parkinsonism. These behavioural disorders might be associated in part with the disruption of dopaminergic pathways interconnecting the prefrontal cortex and ventral striatum (Ribeyre et al., 1994; Farde et al., 1997; Joyce et al., 1997) .
Cortical D2 receptor binding
Conclusions
In contrast to parkin-negative YOPD and IPD patients, parkin-linked parkinsonism is associated with more widespread and severe disruption of striatal dopaminergic and midbrain catecholaminergic and serotoninergic pathways. Reductions of postsynaptic D2 receptors in parkin-linked parkinsonism have been localized in striatal, thalamic and cortical areas. This may be a direct consequence of the genetic defect per se or a higher susceptibility to dopaminergic treatment.
